Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review

Authors:
  • CTCaroline Triby
    Caroline Triby
  • BSBohane Slama
    Bohane Slama
  • XFXavier Fontana
    Xavier Fontana
  • JBJean-Marc Broglia
    Jean-Marc Broglia
  • GLGérard Lepeu
    Gérard Lepeu
  • PCPatricia Carrier
    Patricia Carrier
  • IPIsabelle Peyrottes
    Isabelle Peyrottes
  • JDJacques Darcourt
    Jacques Darcourt
  • PBPierre-Yves Bondiau
    Pierre-Yves Bondiau
  • ATAntoine Thyss
    Antoine Thyss

Abstract
Multicenter, retrospective study of standard-dose RIT in eight heavily pre-treated patients with CD20-positive follicular lymphoma who had relapsed after previous autologous bone marrow transplantation (ABMT). Patients underwent nine courses of (90)Y-ibritumomab tiuxetan (0.3 or 0.4 mCi/kg body weight). Responses included five CR, two PR, one SD and one PD. Median DFS was 12 months with median follow-up of 17 months and 1-year OS was 83% (7/8 patients). Grade 4 thrombocytopenia occurred in 7/9 treatments, with no episodes of bleeding, and only two patients received a platelet transfusion. One patient, who had 20% bone marrow involvement at the time of relapse diagnosis, presented with Grade 4 thrombocytopenia and Grade 4 neutropenia and died of septic shock 6 months after RIT. One other case of Grade 4 neutropenia, without a serious infectious syndrome, was observed. Standard-dose RIT seems feasible and potentially effective after ABMT in correctly selected patients with follicular lymphoma.

This publication has 26 references indexed in Scilit: